Cargando…
Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System
INTRODUCTION: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. OBJECTIVES: The objective of the current stu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567455/ https://www.ncbi.nlm.nih.gov/pubmed/28600751 http://dx.doi.org/10.1007/s40801-017-0110-0 |
_version_ | 1783258736240885760 |
---|---|
author | Nzolo, Didier Anto, Francis Hailemariam, Sarah Bakajika, Didier Muteba, Daniel Makenga, Jean-Claude Mesia, Gautier Nsibu, Celestin Mampunza, Samuel Tona, Gaston |
author_facet | Nzolo, Didier Anto, Francis Hailemariam, Sarah Bakajika, Didier Muteba, Daniel Makenga, Jean-Claude Mesia, Gautier Nsibu, Celestin Mampunza, Samuel Tona, Gaston |
author_sort | Nzolo, Didier |
collection | PubMed |
description | INTRODUCTION: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. OBJECTIVES: The objective of the current study was to describe the central and peripheral nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC). METHODS: This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009–2013 and focused on central and peripheral nervous system disorders. Relevant demographic, clinical, and parasitological data, including age, sex, area of residence, adverse events, and parasite density were extracted. Descriptive statistics were analyzed using Stata 12. RESULTS: A total of 52 ICSRs related to ivermectin intake were available in VigiBase, with 51 (98.1%) from the Province of Equateur. All patients had central and peripheral nervous system disorders; 25 (48.1%) had altered mental status. Of these, 23 (92.0%) satisfied the criteria for “probable/possible Loa loa encephalopathy temporally related to mectizan(®)” (PLERM). The most frequent nervous system disorders among patients with PLERM were coma (74%), stupor (30%), headache (22%), and abnormal gait (22%). There were, on average, 2149.1 microfilariae per ml (mf/ml) in peripheral blood [95% confidence interval (CI) 463.6–3834.6; n = 23]. Post-treatment, 61% of PLERM cases had <1000 L. loa mf/ml of blood. One patient had microfilariae in the cerebrospinal fluid rather than the peripheral blood. We found 21.4% co-infection with Plasmodium falciparum and 4% mortality. CONCLUSION: PLERM may occur at even low peripheral blood concentrations of microfilaria. |
format | Online Article Text |
id | pubmed-5567455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-55674552017-09-11 Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System Nzolo, Didier Anto, Francis Hailemariam, Sarah Bakajika, Didier Muteba, Daniel Makenga, Jean-Claude Mesia, Gautier Nsibu, Celestin Mampunza, Samuel Tona, Gaston Drugs Real World Outcomes Original Research Article INTRODUCTION: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-endemic. OBJECTIVES: The objective of the current study was to describe the central and peripheral nervous system disorders that occurred after mass administration of ivermectin in Democratic Republic of Congo (DRC). METHODS: This is a retrospective descriptive study involving a review of data on adverse events related to mass administration of ivermectin. Data on reported serious adverse events following mass administration of ivermectin in the DRC were extracted from the World Health Organization (WHO) Global individual case safety report (ICSR) database (VigiBase). The review covered the period 2009–2013 and focused on central and peripheral nervous system disorders. Relevant demographic, clinical, and parasitological data, including age, sex, area of residence, adverse events, and parasite density were extracted. Descriptive statistics were analyzed using Stata 12. RESULTS: A total of 52 ICSRs related to ivermectin intake were available in VigiBase, with 51 (98.1%) from the Province of Equateur. All patients had central and peripheral nervous system disorders; 25 (48.1%) had altered mental status. Of these, 23 (92.0%) satisfied the criteria for “probable/possible Loa loa encephalopathy temporally related to mectizan(®)” (PLERM). The most frequent nervous system disorders among patients with PLERM were coma (74%), stupor (30%), headache (22%), and abnormal gait (22%). There were, on average, 2149.1 microfilariae per ml (mf/ml) in peripheral blood [95% confidence interval (CI) 463.6–3834.6; n = 23]. Post-treatment, 61% of PLERM cases had <1000 L. loa mf/ml of blood. One patient had microfilariae in the cerebrospinal fluid rather than the peripheral blood. We found 21.4% co-infection with Plasmodium falciparum and 4% mortality. CONCLUSION: PLERM may occur at even low peripheral blood concentrations of microfilaria. Springer International Publishing 2017-06-09 /pmc/articles/PMC5567455/ /pubmed/28600751 http://dx.doi.org/10.1007/s40801-017-0110-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Nzolo, Didier Anto, Francis Hailemariam, Sarah Bakajika, Didier Muteba, Daniel Makenga, Jean-Claude Mesia, Gautier Nsibu, Celestin Mampunza, Samuel Tona, Gaston Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System |
title | Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System |
title_full | Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System |
title_fullStr | Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System |
title_full_unstemmed | Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System |
title_short | Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System |
title_sort | central and peripheral nervous system disorders following ivermectin mass administration: a descriptive study based on the democratic republic of congo pharmacovigilance system |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567455/ https://www.ncbi.nlm.nih.gov/pubmed/28600751 http://dx.doi.org/10.1007/s40801-017-0110-0 |
work_keys_str_mv | AT nzolodidier centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT antofrancis centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT hailemariamsarah centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT bakajikadidier centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT mutebadaniel centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT makengajeanclaude centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT mesiagautier centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT nsibucelestin centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT mampunzasamuel centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem AT tonagaston centralandperipheralnervoussystemdisordersfollowingivermectinmassadministrationadescriptivestudybasedonthedemocraticrepublicofcongopharmacovigilancesystem |